A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Interleukin-2, CD4 Lymphocyte Count, Anti-HIV Agents
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Have a CD4 cell count greater than or equal to 300 cells/mm3. Are at least 18. Have been on antiretroviral therapy for at least 7 days prior to study entry. Exclusion Criteria You will not be eligible for this study if you: Abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that would affect your safety or ability to complete the study. Have a history of cancer (other than Kaposi's sarcoma), an AIDS-defining illness, a central nervous system (CNS) abnormality, or an autoimmune/inflammatory disease. Are pregnant or breast-feeding. Have ever received IL-2.
Sites / Locations
- Hospital de Clinicas 'Jose de San Martin' C601-040 CRS
- Hospital F.J. Muniz C601-050 CRS
- Hospital General de Agudos J.M. Ramos Mejia CPCRA CRS
- Hospital Italiano de Buenos Aires C601-020 CRS